Literature DB >> 8765175

Prognostic value of histopathological therapeutic effects and mitotic index in locally advanced breast cancers after neoadjuvant chemotherapy.

S Akashi-Tanaka1, H Tsuda, H Fukuda, T Watanabe, T Fukutomi.   

Abstract

A study was conducted to examine whether or not the histopathological therapeutic effects of preoperative chemotherapy could be useful for determining prognosis in women with locally advanced breast cancer. The patients were 37 women with locally advanced breast cancer who received preoperative chemotherapy between 1977 and 1987. The histological grade of malignancy (HGM) and histopathological therapeutic effects of chemotherapy (TEf) were examined in resected specimens. Patients with HGM 3 showed a poorer 10-year overall survival (38%) than those with HGM 1 or 2 (62%). Patients showing a better histopathological response (TEf 1b plus 2) had a poorer 10-year overall survival (20%) than those with a poorer response (TEf 0 plus 1a) (60%). Therapeutic effects were significantly related to histological grade, nuclear atypia and mitotic index (p = 0.03, 0.005 and 0.002, respectively). Histopathological therapeutic effects were not directly correlated with patient prognosis. Cox proportional hazard regression analysis revealed that mitotic index was the most significant prognostic factor related to 10-year overall survival.

Entities:  

Mesh:

Year:  1996        PMID: 8765175     DOI: 10.1093/oxfordjournals.jjco.a023214

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  4 in total

Review 1.  Prognostic value of proliferation in invasive breast cancer: a review.

Authors:  P J van Diest; E van der Wall; J P A Baak
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

2.  Ki-67 biomarker in breast cancer of Indian women.

Authors:  Amit V Patil; Rajeev Singhai; Rahul S Bhamre; Vinayak W Patil
Journal:  N Am J Med Sci       Date:  2011-03

3.  Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.

Authors:  Russell Burcombe; George D Wilson; Mitch Dowsett; Ifty Khan; Paul I Richman; Frances Daley; Simone Detre; Andreas Makris
Journal:  Breast Cancer Res       Date:  2006-06-21       Impact factor: 6.466

4.  Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer.

Authors:  R J Burcombe; A Makris; P I Richman; F M Daley; S Noble; M Pittam; D Wright; S A Allen; J Dove; G D Wilson
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.